CD86 and neoplasm: Last, there was an upregulation of surface CD80 and CD86 expression in the Ly6C+MHC-II+ macrophages (Supplementary Fig S8E), suggesting that anti-PDL-L1 therapy attenuated the loss of inflammatory gene expression following tumour infiltration.